^
    Back
    Association details:
    Biomarker:RET overexpression
    Cancer:Breast Cancer
    Drug:Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Int J Cancer
    Title:

    Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers

    Excerpt:
    Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR.
    DOI:
    10.1002/ijc.29974